Carlsmed CARL 深 沪
交易中 08-05 10:48:55 美东时间
13.365
-0.065
-0.48%
华盛通- 最 高13.45
- 今 开13.45
- 成交量 2.74万股
- 最 低 12.90
- 昨 收 13.43
- 总市值 17.07亿
- 52周最高 17.19
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 8.50
- 委 比 0.00%
- 总股本 1.28亿
- 历史最高 17.19
- 量 比 1.20
- 振 幅 4.10%
- 历史最低 8.50
- 每 手 1
- 风险率 1.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Carlsmed Announces Favorable Reimbursement for aprevo® lumbar Procedures
The Centers for Medicare & Medicaid Services (CMS) has finalized a favorable reimbursement policy for inpatient aprevo® Lumbar spinal fusion procedures, effective October 1, 2026. CMS created three new Medicare Severity-Diagnosis Related Groups (MS-DRGs) 523, 524, and 525 for these procedures, enhancing hospital reimbursement and improving access for patients and surgeons. Carlsmed, the developer of aprevo®, welcomed the decision, emphasizing its...
08-03 12:00
Carlsmed, Inc. To Participate in Upcoming Investor Conferences
Carlsmed, Inc. announced its participation in two upcoming investor conferences: the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 10, 2026, and the Bank of America SMID Cap Virtual Conference with a fireside chat on August 12, 2026, at 11:00 AM ET. A live webcast will be available for the Bank of America event, with archived access on the company’s investor website. Carlsmed focuses on AI-enabled personalized spine s...
07-27 20:01
Carlsmed Inc. to Report Second Quarter 2026 Financial Results on August 5, 2026
Carlsmed, Inc. (Nasdaq: CARL), a medical technology company specializing in AI-enabled personalized spine surgery solutions, announced it will release its Q2 2026 financial results after market close on August 5, 2026. Management will host a conference call and webcast at 1:30 PM Pacific Time. The live webcast and replay will be available on the company’s investor website.
07-22 20:01
美股大行评级 | 潜在涨幅392.61%！Chardan Capital维持EyePoint"买入"评级，上调目标价至65美元
今日重点评级关注：Chardan Capital：维持EyePoint"买入"评级，目标价从29美元升至65美元；康托·菲茨杰拉德：维持Hyperliquid Strategies"超配"评级，目标价从8美元升至18.4美元
07-02 18:41
Needham Initiates Coverage On Carlsmed with Buy Rating, Announces Price Target of $17
Needham analyst David Saxon initiates coverage on Carlsmed (NASDAQ:CARL) with a Buy rating and announces Price Target of $17.
07-01 19:56
Carlsmed shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY2026 sales guidance above estimates.
Carlsmed shares are trading higher after the company reported better-than-expec...
05-06 23:03
Carlsmed Q1 2026 Earnings Call: Complete Transcript
Carlsmed (NASDAQ:CARL) released first-quarter financial results and hosted an e...
05-06 05:27
Carlsmed Raises FY2026 Sales Guidance from $70.000M-$75.000M to $72.000M-$77.000M vs $72.807M Est
Carlsmed (NASDAQ:CARL) raises FY2026 sales outlook from $70.000 million-$75.000 million to $72.000 million-$77.000 million vs $72.807 million estimate.
05-06 04:03
Carlsmed Q1 EPS $(0.32) Beats $(0.41) Estimate, Sales $16.100M Beat $14.984M Estimate
Carlsmed (NASDAQ:CARL) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.41) by 21.95 percent. The company reported quarterly sales of $16.100 million which beat the analyst
05-06 04:03
Earnings Scheduled For May 5, 2026
Companies Reporting Before The Bell • Repligen (NASDAQ:RGEN) is projected to re...
05-05 19:12
